Recombinant vector constructed from an encoding gene of a nitrilase mutant, a recombinant genetic engineered strain and application thereof

US11525131B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11525131-B2
Application numberUS-202117165319-A
CountryUS
Kind codeB2
Filing dateFeb 2, 2021
Priority dateFeb 14, 2018
Publication dateDec 13, 2022
Grant dateDec 13, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention discloses a recombinant vector constructed from an encoding gene of a nitrilase mutant, a recombinant genetic engineered strain and application thereof the nucleotide sequence of the gene is shown in SEQ ID No. 5, and the amino acid sequence of the mutant is shown in SEQ ID No. 6. In the present invention, by the protein molecular modification, thermostability of the purified nitrilase LNIT5 is increased by up to 4.5 folds; and by utilizing recombinant E. coli containing the nitrilase mutant to hydrolyze 1-cyanocyclohexylacetonitrile at a high temperature (45° C.), product tolerance is increased, activity of NITS-L201F is increased by 20%, and the mutant NITLNIT5-AcN can completely hydrolyze 750 mM 1-cyanocyclohexylacetonitrile within 8 hours and achieve an doubled conversion rate. Therefore, the mutants obtained by the present invention have a good application prospect in efficiently catalyzing 1-cyanocyclohexylacetonitrile to synthesize gabapentin intermediate, 1-cyanocyclohexyl acetic acid.

First claim

Opening claim text (preview).

The invention claimed is: 1. A recombinant vector constructed from comprising an encoding gene of a nitrilase mutant, wherein the nucleotide sequence of the gene is shown in SEQ ID No:5. 2. The recombinant vector as claimed in claim 1 , wherein the amino acid sequence of the mutant is shown in SEQ ID No:6. 3. The recombinant vector as claimed in claim 1 , wherein the gene has the nucleotide sequence set forth in SEQ ID No:7. 4. The recombinant vector as claimed in claim 3 , wherein the gene is obtained as follows: firstly, designing primers, using PCR amplification to obtain a nucleotide sequence that contains homologous arms and the nucleotide sequence of SEQ ID No:7; then, designing primers, using PCR amplification to obtain a linearized vector sequence containing homologous arms and the nucleotide sequence corresponding to the amino acids at region 1-323 of the nitrilase amino acid sequence set forth in SEQ ID NO:2 derived from an uncultured microorganism; fusing the two nucleotide sequences via homologous recombination to obtain the amino acid sequence of the nitrilase mutant. 5. The recombinant vector as claimed in claim 4 , wherein the nucleotide sequence coding the amino acids at positions 324-371 is shown in SEQ ID No:7. 6. The recombinant vector as claimed in claim 4 , wherein obtaining the gene further comprises designing primers I-f and I-r, using PCR amplification to obtain a nucleotide sequence that contains homologous arms and the nucleotide sequence of SEQ ID No:7; primer name primer sequence (5′ to 3′) I-f ACCTGGACGAAGAAGGTCGTCTGGATGTTAACACGCGTTCC I-r TTGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGC 7. The recombinant vector as claimed in claim 4 , wherein obtaining the gene further comprises designing primers P-f and P-r, using PCR amplification to obtain a linearized vector sequence containing homologous arms and the nucleotide sequence corresponding to amino acids at region 1-323 of the nitrilase amino acid sequence set forth in SEQ ID NO:2; primer name primer sequence (5′ to 3′) P-f TGAGATCCGGCTGCTAACAAA P-r ACGACCTTCTTCGTCCAGGTAA 8. The recombinant vector as claimed in claim 1 , wherein the gene is ligated to an expression vector pET-28b(+) by enzymatic cutting and ligating to construct a recombinant vector pET-28b(+)-LNIT5. 9. A recombinant genetically engineered strain transformed by with the recombinant vector as claimed in claim 1 . 10. The recombinant genetically engineered strain as claimed in claim 9 , wherein the recombinant genetically engineered strain is obtained by transforming the recombinant vector into a host cell, wherein the host cell is E. coli BL21 (DE3).

Assignees

Inventors

Classifications

  • Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

  • C12N9/78Primary

    acting on carbon to nitrogen bonds other than peptide bonds (3.5) · CPC title

  • Nitriles (-CN) · CPC title

  • Nitrilase (3.5.5.1) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11525131B2 cover?
The present invention discloses a recombinant vector constructed from an encoding gene of a nitrilase mutant, a recombinant genetic engineered strain and application thereof the nucleotide sequence of the gene is shown in SEQ ID No. 5, and the amino acid sequence of the mutant is shown in SEQ ID No. 6. In the present invention, by the protein molecular modification, thermostability of the purif…
Who is the assignee on this patent?
Univ Zhejiang Technology
What technology area does this patent fall under?
Primary CPC classification C12N9/78. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).